Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-022184
Filing Date
2023-05-15
Accepted
2023-05-15 16:02:29
Documents
48
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fbrx-20230331.htm   iXBRL 10-Q 1605404
2 EX-31.1 fbrx-ex31_1.htm EX-31.1 20510
3 EX-31.2 fbrx-ex31_2.htm EX-31.2 20251
4 EX-32.1 fbrx-ex32_1.htm EX-32.1 11542
5 EX-32.2 fbrx-ex32_2.htm EX-32.2 11591
  Complete submission text file 0000950170-23-022184.txt   5153209

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fbrx-20230331_cal.xml EX-101.CAL 20714
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fbrx-20230331_lab.xml EX-101.LAB 311759
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fbrx-20230331_pre.xml EX-101.PRE 213702
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fbrx-20230331_def.xml EX-101.DEF 107833
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fbrx-20230331.xsd EX-101.SCH 34048
42 EXTRACTED XBRL INSTANCE DOCUMENT fbrx-20230331_htm.xml XML 770297
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38052 | Film No.: 23921830
SIC: 2834 Pharmaceutical Preparations